Radiotherapy Research Seminar Series

Why are we offering this and why would you wish to attend?

Topic: The changing face of clinical trials in GI cancerSpeaker: Professor David Sebag-Montefiore, Consultant Clinical Oncologist St James’s University Hospital LeedsDate: Friday 6th Feb 2015, 8.30 for coffee(F514) 9am startVenue: F518 Robert Winston Building.

There is an opportunity to gain an 'electronic badge' to show skills gained by attending, following completion of a post event survey. If you would like to attend please contact Jo

Doughty(j.p.doughty@shu.ac.uk)

If this is during clinical placement please seek the agreement of your PDF and use your study time, although the sessions are only an hour you can use the rest of the time to

complete study on site if you wish.

1. We would like you to feel included and informed in the research activity of the team

2. Will allow you to see what is involved in research

3. You may become inspired to move forward in research

14,000 patients are diagnosed with rectal cancer and 1,000 patients with anal cancer in the UK each year. These two disease sites will be used to illustrate the impact of reported clinical trials on clinical practice (MRC CR07 and ACT1)

Future clinical trials will require more complex design, international collaboration and account for changes in radiotherapy techniques.

Examples will be used to illustrate how these challenges may be met including the ARISTOTLE, STAR TREC and proposed PLATO trials

Professor David Sebag-Montefiore

David Sebag-Montefiore is the Audrey and Stanley Burton Professor of Clinical Oncology at the University of Leeds and Honorary Consultant at Leeds Cancer Centre.

His research interests include clinical trials and radiotherapy research with a focus on gastrointestinal cancers. He is the Chief Investigator of the CR07 and ARISTOTLE trials and co-lead for the CRUK STAR TREC trial. He is a member of the NCRI Colorectal study group, its anorectal subgroup, CTRads workstream 3 and Chairs Cancer Research UK’s Clinical Trial Awards and Advisory Committee.

He has over 80 peer reviewed publications including high impact outputs in Lancet, Lancet Oncology and JCO. He teaches on the Sheffield Part II FRCR course and at the European School of Oncology Masterclasses.